Posted on behalf of Jane Qiu

It was strange bedfellows indeed at a meeting on regenerative medicine in Beijing last month. At the opening ceremony Hu Xiang, chief executive officer of Beike Biotechnology in Shenzhen, gave a speech as a key sponsor, sharing the podium with government officials and influential public figures including China’s health minister Chen Zhu.

With multi-lingual websites and promoting agencies in the US, Europe, Thailand and India, Beike has earned international notoriety by recruiting patients around the world to receive untested stem-cell therapies in China. It supplies stem cells to a network of over two dozen hospitals in China and one in Thailand for treating a myriad of diseases. Hu told Nature that Beike has treated over 5,000 patients since 2005. The company claims to be conducting clinical research, but is yet to publish any data in major international peer-reviewed journals. (See related Nature story here.)

Ellis Rubinstein, president of the New York Academy of Sciences which cohosted the meeting, says that he did not know Beike’s track record, but was grateful that someone had put down “some serious money to support the event”; several major pharmaceutical companies had pulled out as sponsors. “We are having a financial crisis in a good part of the world. That’s the reality in which we are operating,” he says.

Some researchers, like Zhao Chunhua of the Chinese Academy of Medical Sciences, were deeply concerned. “Having Beike sharing the podium with such a distinguished list of speakers has simply sent out a very wrong signal,” he says.